Tiziana Life Sciences (TLSA) announced that dosing has commenced at the fourth clinical site in its ongoing Phase 2 trial evaluating intranasal foralumab in patients with non-active secondary progressive multiple sclerosi, na-SPMS. The University of Massachusetts, UMass, has now joined Brigham and Women’s Hospital, Yale Multiple Sclerosis Center, and Johns Hopkins University Autoimmunity Center of Excellence in actively dosing participants.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSA:
- Tiziana Life Sciences Expands Phase 2 Trial for Multiple Sclerosis Treatment
- Tiziana Life announces dosing at JHU, part of Phase 2 trial of foralumab
- Tiziana Life Sciences files $250M mixed securities shelf
- Tiziana Life Sciences announces dosing of new patients at Yale MS Center
- Tiziana Life Sciences CEO to Present at ROTH Conference